Actively Recruiting

Phase 2
Age: 18Years - 70Years
All Genders
NCT06254560

Rituximab for Serious Aplastic Anemia With Platelet Transfusion Refractoriness

Led by Institute of Hematology & Blood Diseases Hospital, China · Updated on 2024-02-12

20

Participants Needed

1

Research Sites

253 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Due to long-term dependence on platelet transfusion, some severe aplastic anemia (SAA) patients suffer platelet transfusion refractoriness (PTR). Unlike immune thrombocytopenia (ITP), glucocorticoids and human immunoglobulin (IVIg) are generally ineffective for PTR. Due to the lack of effective intervention methods, patients with PTR suffer increased platelet transfusions, bleeding events and treatment costs, prolonged hospital stays, and decreased survival rate. SAA with PTR has become a challenge for physicians. The experiment aims to explore the efficacy of rituximab in the treatment of SAA with PTR, and establish a new effective, safe treatment method with relatively low treatment cost.

CONDITIONS

Official Title

Rituximab for Serious Aplastic Anemia With Platelet Transfusion Refractoriness

Who Can Participate

Age: 18Years - 70Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Initial diagnosis of severe aplastic anemia with platelet transfusion refractoriness
  • Age greater than 18 years
  • Any gender
Not Eligible

You will not qualify if you...

  • Allergy to rituximab
  • Severe active infection
  • Hypogammaglobulinemia
  • Pregnant or breastfeeding women
  • Heart failure classified as NYHA IV
  • Epilepsy, dementia, or other mental disorders requiring medication that impair understanding or compliance
  • Chronic infections or other chronic diseases posing risk to the study
  • Researchers' judgment deeming participation unsuitable

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences

Tianjin, Tianjin Municipality, China, 300020

Actively Recruiting

Loading map...

Research Team

H

Huang Jinbo, MD.

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here